TP53 and head and neck squamous cell carcinoma: Gendicine, a recombinant human p53 adenovirus, was approved in China by the State Food and Drug Administration (SFDA) in 2003 for the treatment of head and neck squamous cell carcinoma, including oral cancer, usually in combination with radiotherapy.